An analog of human leptin, metreleptin, has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.
In the United States it is approved as replacement therapy to treat the complications of leptin deficiency in patients with congenital zed or acquired generalized lipodystrophy. An analog of human leptin, metreleptin, has been approved in Japan for metabolic disorders including lipodystrophy.
An analog of human leptin, metreleptin, has been approved in Japan for metabolic disorders including lipodystrophy. In the United States it is approved as replacement therapy to treat the complications of leptin deficiency in patients with congenital zed or acquired generalized lipodystrophy.
An analog of human leptin, metreleptin, has been approved in Japan for metabolic disorders including lipodystrophy. In the United States it is approved as replacement therapy to treat the complications of leptin deficiency in patients with congenital zed or acquired generalized lipodystrophy.